Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer.
Ghali F, Patel D, Jamieson C, Parsons J, McKay R. Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer. Journal Of Clinical Oncology 2020, 38: 203-203. DOI: 10.1200/jco.2020.38.6_suppl.203.Peer-Reviewed Original ResearchProstate cancerOverall survivalActivating mutationsDe novo metastatic diseaseAdvanced prostate cancerSomatic activating mutationsEligible patientsAdvanced diseaseGleason 8Visceral metastasesClinical characteristicsMetastatic diseaseOverall cohortMedian ageMedian timePCa patientsDisease characteristicsOutcome parametersCRPC developmentBiomarker statusDisease progressionMultiple malignanciesTreatment strategiesClinical significanceBRCA1/2 alterationsMulticenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma.
Bradshaw A, Ghali F, Miller N, Keiner C, Dutt R, Meagher M, Yim K, Patel D, Uzzo R, Lane B, Capitanio U, Derweesh I. Multicenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 758-758. DOI: 10.1200/jco.2020.38.6_suppl.758.Peer-Reviewed Original ResearchRecurrence-free survivalCancer-specific survivalKaplan-Meier analysisRenal cell carcinomaPT3a renal cell carcinomaOverall survivalMultivariable analysisSecondary outcomesPrimary outcomeCell carcinomaT3a renal cell carcinomaPathologic tumor sizePoor oncologic outcomesRegression multivariable analysisClear cell histologyLog-rank testPre-operative imagingPositive margin rateHigh recurrence rateAdvanced diseaseCell histologyOncologic outcomesVenous involvementMulticenter analysisOS rates